2026-05-08T20:02:32Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/169462024-09-27T08:44:12Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Toribio-Fernandez, Raquel author Ceron, Carlos author Tristão-Pereira, Catarina author Fernandez-Nueda, Irene author Perez-Castillo, Ana author Fernandez-Ferro, Jose author Moro, Maria Angeles author Ibáñez, Borja author Fuster, Valentin author Cortes-Canteli, Marta author 2023-01-12 Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed, CVD signatures such as cerebral microbleeds, micro-infarcts, atherosclerosis, cerebral amyloid angiopathy and a procoagulant state are highly associated with AD. However, AD and CVD co-development and the molecular mechanisms underlying such associations are not understood. Here, we review the evidence regarding the vascular component of AD and clinical studies using anticoagulants that specifically evaluated the development of AD and other dementias. Most studies reported a markedly decreased incidence of composite dementia in anticoagulated patients with atrial fibrillation, with the highest benefit for direct oral anticoagulants. However, sub-analyses by differential dementia diagnosis were scarce and inconclusive. We finally discuss whether anticoagulation could be a plausible preventive/therapeutic approach for AD and, if so, which would be the best drug and strategy to maximize clinical benefit and minimize potential risks. Br J Pharmacol . 2023 Jan 12. 10.1111/bph.16032 1476-5381 British journal of pharmacology 36633908 http://hdl.handle.net/20.500.12105/16946 Oral anticoagulants: A plausible new treatment for Alzheimer's disease?